Dr. Brian Kennedy is the current President and CEO of the Buck Institute for Research on Aging. The Buck Institute is the nation's first independent research facility focused solely on understanding the connection between aging and chronic disease. The Buck Institute's mission is to increase the healthy years of life.

Brian's innovative work in the biology of aging began when he was a doctoral student at MIT.  Under the guidance of MIT Professor Leonard Guarente, he contributed to the first studies to show that a class of proteins called Sirtuins influence aging.  Currently, he studies the pathways that modulate longevity in life forms ranging from yeast to mice.  A major focus of his current research is to study the target of the rapamycin (TOR) pathway. TOR generated excitement in the age research field when it was shown recently that the drug rapamycin can extend mouse lifespan. One of the goals of his research is to determine whether pathways like TOR can be regulated to treat the diseases of aging.  Specifically, Brian's lab focuses on cardiovascular disease and metabolic syndromes like type II diabetes.  Brian also studies the genetic mutations underlying diseases such as dilated cardiomyopathy, muscular dystrophy and Hutchinson-Gilford Progeria Syndrome, which resembles premature aging.  The mutations being studied affect a class of molecules called A-type nuclear lamins, and the lab is exploring their roles in health and disease.

Brian earned his PhD in Biology at Massachusetts Institute of Technology, where he took part in groundbreaking studies on aging. He completed postdoctoral training at the Massachusetts General Hospital Cancer Center in Charlestown, Massachusetts. Brian was an associate professor in the biochemistry department at the University of Washington in Seattle when he was appointed the President and the Chief Executive Officer of the Buck Institute in 2010.